The characteristics and outcome of 58 patients with acute myelogenous leukemia (AML) who experienced relapse after a first remission duration longer than 18 months (late-relapse AML) were analyzed and compared with those of 278 patients with earlier relapses. Late-relapse AML was associated with a lower incidence of antecedent hematologic disorder, leukocytosis, and elevated creatinine and lactic acid dehydrogenase (LDH) levels. A favorable karyotype (inversion of chromosome 16; translocations between chromosomes 8 and 21, or 15 and 17) was more frequent in patients whose first remission was 12 months or longer compared with less than 12 months (30% v 10%; P less than .0001). An unfavorable karyotype (chromosome 5 and 7 abnormalities, trisomy 8, other changes) was more frequent in the latter category (16% v 42%; P less than .0001). Thirty-seven of the 58 patients (64%) with late-relapse AML achieved complete remission (CR). The incidence of CR increased significantly with an increased first remission duration from less than 12, 12 to 18, and greater than 18 months (17% v 41% v 64%; P less than .0001), while the incidence of resistant disease was significantly lower (59% v 36% v 19%; P less than .0001). When effective antileukemic regimens were considered, remission rates were also significantly increased by the duration of first remission (24% v 48% v 72%; P less than .001). Compared with patients with earlier relapse, those with late-relapse AML had a longer median survival from salvage therapy (3.5 v 12 months; P less than .01), and longer median second remission durations (3.5 v 11 months; P less than .01). We conclude that late-relapse AML has unique clinical, cytogenetic, and prognostic characteristics, and remains extremely sensitive to chemotherapy with a potential cure fraction. The duration of first remission is an important prognostic parameter in AML relapse and may be useful in the design and analysis of future salvage programs.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.1988.6.2.232DOI Listing

Publication Analysis

Top Keywords

late-relapse aml
20
characteristics outcome
8
outcome patients
8
acute myelogenous
8
myelogenous leukemia
8
remission
8
remission duration
8
patients earlier
8
months longer
8
duration remission
8

Similar Publications

Article Synopsis
  • - The AML-05 study focused on evaluating a risk-based treatment approach for children with acute myeloid leukemia (AML), determining that allogeneic hematopoietic cell transplantation (allo-HCT) wasn’t necessary for low- or intermediate-risk patients in their first complete remission.
  • - A retrospective analysis identified key prognostic factors for survival in 79 pediatric patients who underwent allo-HCT, highlighting umbilical cord blood (UCB) as a particularly favorable donor source for low-risk patients, along with late relapse being advantageous for intermediate-risk patients.
  • - The study found significant differences in three-year outcomes like overall survival (OS) and event-free survival (EFS) between low- and intermediate-risk groups, suggesting
View Article and Find Full Text PDF

Several studies reported that patients with acute myeloid leukemia (AML) who remain in long-term remission after allogeneic or autologous transplant have a shorter life expectancy, compared to the general population. However, little is known about the life expectancy of adult long-term survivors of AML who were treated with chemotherapy alone without a transplant and there have been no comparisons with survival among the general population. The current study indicates that the life expectancy of AML patients who achieved and maintained CR for at least 3 years is shorter than expected for age in the US population.

View Article and Find Full Text PDF

Late relapse, beyond 2 years following alloHSCT for AML, is rare. Among the 376 patients allografted for AML in our center between 1990 and 2016, 142 (38%) relapsed. The majority (68%) of relapses occurred during the first year following transplantation.

View Article and Find Full Text PDF

ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia.

Malays J Pathol

April 2023

Universiti Putra Malaysia, Faculty of Medicine and Health Sciences, Department of Pathology, Selangor, Malaysia.

Introduction: Acute myeloid leukaemia (AML) is a heterogeneous malignant disease with a high degree of treatment failure using chemotherapy. Leukaemia stem cells (LSCs) are CD34+CD38- early progenitors associated with poor prognosis in AML. A unique LSC phenotype that excludes rare normal haematopoietic stem cells (HSC) is still elusive.

View Article and Find Full Text PDF

The majority of patients with acute myeloid leukemia (AML) with the mutation achieve remission with intensive chemotherapy. However, many patients subsequently relapse, which occurs frequently within the first 2-3 years after therapy, while late relapse after more than 10 years is rare and can also represent secondary/therapy-associated AML without the NPM1 mutation. Here, we present a case of -mutated AML that developed medullary and extramedullary relapse 17 years after allogeneic stem cell transplantation, maintaining the mutation and all other genetic alterations detected at first diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!